• 
... 
nc :::: .. 
Medifocus I •• •• 
• 
December 10, 2019 

Marge Watchorn, Deputy Director, Practitioner Services 
Centers for Medicare and Medicaid Services 
Department of Health and Human Services 
Attention CMS-1693-IFC 
P. 0. Box 8010 
Baltimore, MD 21244-8016 

Re: Our Request /Petition for Reevaluation to the Recent Misvalue of CPT code 53852 
Dear Mrs. Watchorn: 

Happy Holidays! We understand this is a very busy time for you and would like to follow up with you about the letter we sent to you on November 12, 2019. The letter states why we believe the CPT code for our Prolieve (3rd Generation) and only Thermodilatation therapy device, should be reevaluated and was not justified for the major reduction in reimbursement like other (1 st and 2nd Generation) Thermotherapy treatment devices. Without the reevaluation as stated we, and approximately 200 Urologists in the USA who provide the Prolieve treatment in their offices, can no longer economically make this treatment available to the many patients who can benefit by its usage. 
We believe our Prolieve treatment provides significant clinical safety and efficacy advantages for the patients as well as dramatically saves the overall cost of healthcare for a large number of men with BPH. Without the time sensitive revaluation, it will reduce the treatment options to what the urologists can offer in their offices and for the benefits of their patients and to the economic well-being of Medifocus Inc. Over 100,000 men in the USA have successfully been treated with Prolieve and it is our desire to have this available to many more. 

JM/fre 

cc: AMA RUC/AUA CPT Committee 
Medilo .. us, lnL. IJ.?40 Old Cc lumbia Ro.id. ',UJt~ <.;, Columbrn, MD 21046 !'hone ( i 10) 290-57 34 lax (4 I Cl) 290-7 25, 



